Global Chloroquine Market Size By Type (Injectables, Capsules), By Application (Arthrophlogosis, Malaria), By Region, And Segment Forecasts, 2023 to 2032

The Global Chloroquine Market was valued at USD 438.2 million in 2023 and is projected to reach USD 675.1 million by 2031, growing at a CAGR of 5.6% during the forecast period from 2023 to 2031. Chloroquine, a well-established antimalarial drug, witnessed renewed interest during the COVID-19 pandemic due to its antiviral potential. While its role in COVID-19 treatment has diminished, the market continues to grow steadily due to ongoing demand in malaria-endemic regions, its application in autoimmune diseases such as rheumatoid arthritis and lupus, and emerging research exploring new therapeutic avenues.

Drivers:

1. Prevalence of Malaria in Endemic Regions:

The continued prevalence of malaria in parts of Africa, Asia, and Latin America drives the demand for chloroquine as a first-line or adjunct treatment, particularly in areas with resistance to newer therapies.

2. Use in Autoimmune Diseases:

Chloroquine and its derivative, hydroxychloroquine, are widely prescribed for autoimmune conditions such as systemic lupus erythematosus (SLE) and rheumatoid arthritis, fueling market demand beyond antimalarial use.

3. Emerging Therapeutic Applications:

Research into chloroquine’s potential in treating cancer, viral infections, and metabolic disorders is expanding its clinical utility and investment appeal.

Restraints:

1. Drug Resistance Concerns:

The emergence of chloroquine-resistant strains of Plasmodium falciparum in several regions restricts its effectiveness and use, particularly in sub-Saharan Africa.

2. Safety and Side Effects:

Long-term use of chloroquine is associated with retinopathy, cardiotoxicity, and other adverse effects, limiting its appeal in chronic therapy settings and prompting cautious regulatory oversight.

Opportunity:

1. Expansion into Adjunct Therapies:

Ongoing studies exploring the repurposing of chloroquine in cancer treatment and as an adjuvant in antiviral therapies provide growth potential, particularly in oncology and virology markets.

2. Market Growth in Developing Regions:

Expanding healthcare infrastructure and increasing access to affordable medication in low- and middle-income countries offer lucrative opportunities for chloroquine suppliers and generic manufacturers.

Market by System Type Insights:

Oral Formulations led the market in 2023, favored for their convenience and widespread use in both prophylactic and therapeutic applications. However, injectable formulations are gaining traction in hospital settings, particularly for severe or acute manifestations requiring rapid bioavailability.

Market by End-use Insights:

Hospitals & Clinics held the largest market share in 2023, driven by higher patient volumes and formal treatment protocols. The retail pharmacy segment is expected to grow steadily due to self-medication practices in malaria-prone areas and increased awareness of chloroquine's broader applications.

Market by Regional Insights:

Africa accounted for the largest market share in 2023, due to the high malaria burden and widespread use of chloroquine in both prevention and treatment. Asia-Pacific is emerging as the fastest-growing region, with India and Southeast Asia exhibiting significant demand growth, supported by government health initiatives and generic drug production. North America and Europe maintain stable demand driven by autoimmune disease management and research use.

Competitive Scenario:

Key players in the global chloroquine market include Sanofi S.A., Bayer AG, Ipca Laboratories Ltd., Zydus Lifesciences, Teva Pharmaceuticals, Novartis AG, Mylan N.V., Advanz Pharma, Hikma Pharmaceuticals, and Sun Pharmaceutical Industries Ltd. These companies focus on generic production, API development, regulatory compliance, and expansion into emerging markets.

Notable Developments:

2023: Ipca Laboratories received WHO prequalification for its chloroquine formulations to support malaria programs in Africa.

2024: Teva Pharmaceuticals expanded its chloroquine production facilities in Asia to meet increasing regional demand.

2025: Bayer AG initiated clinical trials investigating chloroquine as an adjunct therapy in triple-negative breast cancer treatment.

Scope of Work – Global Chloroquine Market

FAQs:

1) What is the current market size of the Global Chloroquine Market?

The Global Chloroquine Market was valued at USD 438.2 million in 2023.

2) What is the major growth driver of the Global Chloroquine Market?

The continued prevalence of malaria and increased use in autoimmune diseases are major growth drivers.

3) Which is the largest region during the forecast period in the Global Chloroquine Market?

Africa is the largest regional market, driven by high malaria incidence and widespread use.

4) Which segment accounted for the largest market share in the Global Chloroquine Market?

The oral formulation segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Chloroquine Market?

Key players include Sanofi S.A., Bayer AG, Ipca Laboratories, Zydus Lifesciences, and Teva Pharmaceuticals.